Extracellular Vesicles and Their Role in Urologic Malignancies

European Urology

Volumn 70, Issue 2, 2016, Pages 323-331

  Junker, Kerstin ^a   Heinzelmann, Joana ^a   Beckham, Carla ^b   Ochiya, Takahiro ^c   Jenster, Guido ^d  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF ROCHESTER   (United States)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Exosomes; Extracellular vesicles; Kidney cancer; Microvesicles; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; RNA; TUMOR MARKER;

BLADDER CANCER; BODY FLUID; CANCER GROWTH; CANCER PROGNOSIS; CELL COMMUNICATION; CYTOPLASM; DIAGNOSTIC VALUE; EXOSOME; HUMAN; KIDNEY CANCER; KIDNEY FUNCTION; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONTENT; REVIEW; SECRETORY VESICLE; SPERMATOGENESIS; URINARY TRACT CANCER; DIFFERENTIAL DIAGNOSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; URINARY TRACT TUMOR; UROGENITAL SYSTEM;

BIOMARKERS, TUMOR; DIAGNOSIS, DIFFERENTIAL; EXTRACELLULAR VESICLES; HUMANS; PROGNOSIS; UROGENITAL SYSTEM; UROLOGIC NEOPLASMS;

EID: 84975688004     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.02.046     Document Type: Review

References (76)

1. [1] Akers, J.C., Gonda, D., Kim, R., Carter, B.S., Chen, C.C., Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol 113 (2013), 1–11.
2. [2] Duijvesz, D., Luider, T., Bangma, C.H., Jenster, G., Exosomes as biomarker treasure chests for prostate cancer. Eur Urol 59 (2011), 823–831.
3. [3] Zaborowski, M.P., Balaj, L., Breakefield, X.O., Lai, C.P., Extracellular vesicles: composition, biological relevance, and methods of study. BioScience 65 (2015), 783–797.
4. [4] van der Pol, E., Boing, A.N., Gool, E.L., Nieuwland, R., Recent developments on the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. J Thromb Haemost 14 (2016), 48–56.
5. [5] Witwer KW, Buzás EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. In press. http://dx.doi.org/10.3402/jev.v2i0.20360.
6. [6] Ratajczak, J., Miekus, K., Kucia, M., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20 (2006), 847–856.
7. [7] Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J., Lotvall, J.O., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9 (2007), 654–659.
8. [8] Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., Ochiya, T., Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 285 (2010), 17442–17452.
9. [9] Katsuda, T., Kosaka, N., Takeshita, F., Ochiya, T., The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics 13 (2013), 1637–1653.
10. [10] Skog, J., Wurdinger, T., van Rijn, S., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10 (2008), 1470–1476.
11. [11] Kosaka, N., Izumi, H., Sekine, K., Ochiya, T., microRNA as a new immune-regulatory agent in breast milk. Silence, 1, 2010, 7.
12. [12] Zomer, A., Maynard, C., Verweij, F.J., et al. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell 161 (2015), 1046–1057.
13. [13] Peinado, H., Aleckovic, M., Lavotshkin, S., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18 (2012), 883–891.
14. [14] Roccaro, A.M., Sacco, A., Maiso, P., et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 123 (2013), 1542–1555.
15. [15] Kosaka, N., Iguchi, H., Yoshioka, Y., Hagiwara, K., Takeshita, F., Ochiya, T., Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem 287 (2012), 1397–1405.
16. [16] Ono, M., Kosaka, N., Tominaga, N., et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal, 7, 2014, ra63.
17. [17] Welker, M.W., Reichert, D., Susser, S., et al. Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity. PLoS One, 7, 2012, e30796.
18. [18] Rajendran, L., Honsho, M., Zahn, T.R., et al. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A 103 (2006), 11172–11177.
19. [19] Kuwabara, Y., Ono, K., Horie, T., et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 4 (2011), 446–454.
20. [20] Tanaka, Y., Kamohara, H., Kinoshita, K., et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 119 (2013), 1159–1167.
21. [21] Tian, Y., Li, S., Song, J., et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35 (2014), 2383–2390.
22. [22] Jang, S.C., Kim, O.Y., Yoon, C.M., et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 7 (2013), 7698–7710.
23. [23] Johnsen, K.B., Gudbergsson, J.M., Skov, M.N., Pilgaard, L., Moos, T., Duroux, M., A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta 1846 (2014), 75–87.
24. [24] O'Loughlin, A.J., Woffindale, C.A., Wood, M.J., Exosomes and the emerging field of exosome-based gene therapy. Curr Gene Ther 12 (2012), 262–274.
25. [25] Pitt, J.M., Charrier, M., Viaud, S., et al. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol 193 (2014), 1006–1011.
26. [26] Morse, M.A., Garst, J., Osada, T., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med, 3, 2005, 9.
27. [27] Escudier, B., Dorval, T., Chaput, N., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med, 3, 2005, 10.
28. [28] Marleau, A.M., Chen, C.S., Joyce, J.A., Tullis, R.H., Exosome removal as a therapeutic adjuvant in cancer. J Transl Med, 10, 2012, 134.
29. [29] Lobb RJ, Becker M, Wen Wen S, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles. In press. http://dx.doi.org/10.3402/jev.v4.27031.
30. [30] Momen-Heravi, F., Balaj, L., Alian, S., et al. Alternative methods for characterization of extracellular vesicles. Front Physiol, 3, 2012, 354.
31. [31] Schubert M, Junker K, Heinzelmann J. Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: where do we stand in biomarker development? J Cancer Res Clin Oncol. In press. http://dx.doi.org/10.1007/s00432-015-2089-9.
32. [32] Raimondo, F., Morosi, L., Corbetta, S., et al. Differential protein profiling of renal cell carcinoma urinary exosomes. Mol Biosyst 9 (2013), 1220–1233.
33. [33] Del Boccio, P., Raimondo, F., Pieragostino, D., et al. A hyphenated microLC-Q-TOF-MS platform for exosomal lipidomics investigations: application to RCC urinary exosomes. Electrophoresis 33 (2012), 689–696.
34. [34] Milella, M., Felici, A., Biology of metastatic renal cell carcinoma. J Cancer 2 (2011), 369–373.
35. [35] Zhang, L., Wu, X., Luo, C., et al. The 786-0 renal cancer cell-derived exosomes promote angiogenesis by downregulating the expression of hepatocyte cell adhesion molecule. Mol Med Rep 8 (2013), 272–276.
36. [36] Zhang, Y., Luo, C.L., He, B.C., Zhang, J.M., Cheng, G., Wu, X.H., Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma. Int J Oncol 36 (2010), 133–140.
37. [37] Gu, X., Erb, U., Buchler, M.W., Zoller, M., Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int J Cancer 136 (2015), E74–E84.
38. [38] Diao, J., Yang, X., Song, X., et al. Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3. Med Oncol, 32, 2015, 453.
39. [39] Jiang, X.L., Zhang, Y., Tan, B., Luo, C.L., Wu, X.H., Renal tumor-derived exosomes inhibit hepaCAM expression of renal carcinoma cells in a p-AKT-dependent manner. Neoplasma 61 (2014), 416–423.
40. [40] Bussolati, B., Bruno, S., Grange, C., Ferrando, U., Camussi, G., Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 22 (2008), 3696–3705.
41. [41] Grange, C., Tapparo, M., Collino, F., et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 71 (2011), 5346–5356.
42. [42] Lindoso, R.S., Collino, F., Camussi, G., Extracellular vesicles derived from renal cancer stem cells induce a pro-tumorigenic phenotype in mesenchymal stromal cells. Oncotarget 6 (2015), 7959–7969.
43. [43] Du, T., Ju, G., Wu, S., et al. Microvesicles derived from human Wharton's jelly mesenchymal stem cells promote human renal cancer cell growth and aggressiveness through induction of hepatocyte growth factor. PLoS One, 9, 2014, e96836.
44. [44] Chen, C.L., Lai, Y.F., Tang, P., et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res 11 (2012), 5611–5629.
45. [45] Welton, J.L., Khanna, S., Giles, P.J., et al. Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics 9 (2010), 1324–1338.
46. [46] Jeppesen, D.K., Nawrocki, A., Jensen, S.G., et al. Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors. Proteomics 14 (2014), 699–712.
47. [47] Matullo, G., Naccarati, A., Pardini, B., MicroRNA expression profiling in bladder cancer: the challenge of next generation sequencing in tissues and biofluids. Int J Cancer 138 (2016), 2334–2345.
48. [48] Armstrong, D.A., Green, B.B., Seigne, J.D., Schned, A.R., Marsit, C.J., MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer. Mol Cancer, 14, 2015, 194.
49. [49] Berrondo, C., Flax, J., Kucherov, V., et al. Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS One, 11, 2016, e0147236.
50. [50] Beckham, C.J., Olsen, J., Yin, P.N., et al. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. J Urol 192 (2014), 583–592.
51. [51] Zhang, J.M., Wu, X.H., Zhang, Y., Xia, Y.G., Luo, C.L., Exosomes derived form bladder transitional cell carcinoma cells induce CTL cytotoxicity in vitro [in Chinese]. Zhonghua Zhong Liu Za Zhi 31 (2009), 738–741.
52. [52] Yang, L., Wu, X.H., Wang, D., Luo, C.L., Chen, L.X., Bladder cancer cell-derived exosomes inhibit tumor cell apoptosis and induce cell proliferation in vitro. Mol Med Rep 8 (2013), 1272–1278.
53. [53] Franzen, C.A., Blackwell, R.H., Todorovic, V., et al. Urothelial cells undergo epithelial-to-mesenchymal transition after exposure to muscle invasive bladder cancer exosomes. Oncogenesis, 4, 2015, e163.
54. [54] Ostenfeld, M.S., Jeppesen, D.K., Laurberg, J.R., et al. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res 74 (2014), 5758–5771.
55. [55] Minciacchi, V.R., You, S., Spinelli, C., et al. Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget 6 (2015), 11327–11341.
56. [56] Kharaziha, P., Chioureas, D., Rutishauser, D., et al. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget 6 (2015), 21740–21754.
57. [57] Duijvesz, D., Burnum-Johnson, K.E., Gritsenko, M.A., et al. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS One, 8, 2013, e82589.
58. [58] Nawaz, M., Camussi, G., Valadi, H., et al. The emerging role of extracellular vesicles as biomarkers for urogenital cancers. Nat Rev Urol 11 (2014), 688–701.
59. [59] Tavoosidana, G., Ronquist, G., Darmanis, S., et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci U S A 108 (2011), 8809–8814.
60. [60] Duijvesz, D., Versluis, C.Y., van der Fels, C.A., et al. Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer. Int J Cancer 137 (2015), 2869–2878.
61. [61] Dijkstra, S., Birker, I.L., Smit, F.P., et al. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol 191 (2014), 1132–1138.
62. [62] Donovan, M.J., Noerholm, M., Bentink, S., et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis 18 (2015), 370–375.
63. [63] Huang, X., Yuan, T., Liang, M., et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 67 (2015), 33–41.
64. [64] Korzeniewski, N., Tosev, G., Pahernik, S., Hadaschik, B., Hohenfellner, M., Duensing, S., Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol, 33, 2015 16 e7–22.
65. [65] Bryant, R.J., Pawlowski, T., Catto, J.W., et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106 (2012), 768–774.
66. [66] Lazaro-Ibanez, E., Sanz-Garcia, A., Visakorpi, T., et al. Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes. Prostate 74 (2014), 1379–1390.
67. [67] Bijnsdorp IV, Geldof AA, Lavaei M, Piersma SR, van Moorselaar RJ, Jimenez CR. Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. J Extracell Vesicles. In press. http://dx.doi.org/10.3402/jev.v2i0.22097.
68. [68] Webber, J.P., Spary, L.K., Sanders, A.J., et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 34 (2015), 290–302.
69. [69] Corcoran, C., Rani, S., O'Brien, K., et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One, 7, 2012, e50999.
70. [70] Castellana, D., Zobairi, F., Martinez, M.C., et al. Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res 69 (2009), 785–793.
71. [71] Itoh, T., Ito, Y., Ohtsuki, Y., et al. Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation. J Mol Histol 43 (2012), 509–515.
72. [72] Lundholm, M., Schroder, M., Nagaeva, O., et al. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One, 9, 2014, e108925.
73. [73] Clayton, A., Mitchell, J.P., Court, J., Mason, M.D., Tabi, Z., Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 67 (2007), 7458–7466.
74. [74] Rountree, R.B., Mandl, S.J., Nachtwey, J.M., et al. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res 71 (2011), 5235–5244.
75. [75] Tan, A., De La Pena, H., Seifalian, A.M., The application of exosomes as a nanoscale cancer vaccine. Int J Nanomedicine 5 (2010), 889–900.
76. [76] Kato, T., Mizutani, K., Kameyama, K., et al. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer. Urol Oncol, 33, 2015 385 e15–20.